170 related articles for article (PubMed ID: 19107485)
1. Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile.
Mercier C; Dupuis C; Blesius A; Fanciullino R; Yang CG; Padovani L; Giacometti S; Frances N; Iliadis A; Duffaud F; Ciccolini J
Cancer Chemother Pharmacol; 2009 May; 63(6):1177-80. PubMed ID: 19107485
[TBL] [Abstract][Full Text] [Related]
2. [Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency].
Coursier S; Martelet S; Guillermet A; Emptoz J; Villier C; Bontemps H
Gastroenterol Clin Biol; 2010 Mar; 34(3):218-23. PubMed ID: 20219304
[TBL] [Abstract][Full Text] [Related]
3. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
Caronia D; Martin M; Sastre J; de la Torre J; García-Sáenz JA; Alonso MR; Moreno LT; Pita G; Díaz-Rubio E; Benítez J; González-Neira A
Clin Cancer Res; 2011 Apr; 17(7):2006-13. PubMed ID: 21325291
[TBL] [Abstract][Full Text] [Related]
4. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy.
Ciccolini J; Mercier C; Evrard A; Dahan L; Boyer JC; Duffaud F; Richard K; Blanquicett C; Milano G; Blesius A; Durand A; Seitz JF; Favre R; Lacarelle B
Ther Drug Monit; 2006 Oct; 28(5):678-85. PubMed ID: 17038885
[TBL] [Abstract][Full Text] [Related]
5. Capecitabine: an overview of the side effects and their management.
Saif MW; Katirtzoglou NA; Syrigos KN
Anticancer Drugs; 2008 Jun; 19(5):447-64. PubMed ID: 18418212
[TBL] [Abstract][Full Text] [Related]
6. Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiency.
Gbeto CC; Quaranta S; Mari R; Fanciullino R; Roche C; Nahon S; Solas C; Ouafik L; Lacarelle B; Allegre T; Ciccolini J
Pharmacogenomics; 2019 Aug; 20(13):931-938. PubMed ID: 31486738
[TBL] [Abstract][Full Text] [Related]
7. Uncontrolled hypertriglyceridemia induced by capecitabine: case report and review of the literature.
Bar-Sela G; Haim N
Cancer Chemother Pharmacol; 2009 Apr; 63(5):779-82. PubMed ID: 18641989
[TBL] [Abstract][Full Text] [Related]
8. Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine.
Weger W; Kränke B; Gerger A; Salmhofer W; Aberer E
J Am Acad Dermatol; 2008 Aug; 59(2 Suppl 1):S4-6. PubMed ID: 18625380
[TBL] [Abstract][Full Text] [Related]
9. [Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].
Hooiveld EA; van Kuilenburg AB; Haanen JB; Westermann AM
Ned Tijdschr Geneeskd; 2004 Mar; 148(13):626-8. PubMed ID: 15083629
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
11. Safety of capecitabine: a review.
Mikhail SE; Sun JF; Marshall JL
Expert Opin Drug Saf; 2010 Sep; 9(5):831-41. PubMed ID: 20722491
[TBL] [Abstract][Full Text] [Related]
12. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
[TBL] [Abstract][Full Text] [Related]
13. ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients.
Gonzalez-Haba E; García MI; Cortejoso L; López-Lillo C; Barrueco N; García-Alfonso P; Alvarez S; Jiménez JL; Martín ML; Muñóz-Fernández MA; Sanjurjo M; López-Fernández LA
Pharmacogenomics; 2010 Dec; 11(12):1715-23. PubMed ID: 21142915
[TBL] [Abstract][Full Text] [Related]
14. Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy.
Mercier C; Ciccolini J
Clin Colorectal Cancer; 2006 Nov; 6(4):288-96. PubMed ID: 17241513
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.
Deenen MJ; Dewit L; Boot H; Beijnen JH; Schellens JH; Cats A
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):e201-7. PubMed ID: 23517808
[TBL] [Abstract][Full Text] [Related]
16. Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?
Saif MW; Diasio R
Clin Colorectal Cancer; 2006 Jan; 5(5):359-62. PubMed ID: 16512996
[TBL] [Abstract][Full Text] [Related]
17. Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites.
Besnard T; Renée N; Etienne-Grimaldi MC; François E; Milano G
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jul; 870(1):117-20. PubMed ID: 18562256
[TBL] [Abstract][Full Text] [Related]
18. Capecitabine in gastric cancer.
Okines A; Chau I; Cunningham D
Drugs Today (Barc); 2008 Aug; 44(8):629-40. PubMed ID: 18846273
[TBL] [Abstract][Full Text] [Related]
19. [Oral capecitabine as postoperative adjuvant chemotherapy in stage III colon cancer patients].
Yamaguchi T; Fukuda M; Yasui H; Okazaki S; Kubo K; Tanaka M; Une Y; Setoguchi Y; Hanada K; Moriyama S; Tani M; Murakami T; Okuchi Y; Ogiso S; Hata H; Sakata S; Otani T; Yamato T; Ikai I
Gan To Kagaku Ryoho; 2012 Mar; 39(3):389-93. PubMed ID: 22421765
[TBL] [Abstract][Full Text] [Related]
20. Radiation recall phenomenon secondary to capecitabine: possible role of thymidine phosphorylase.
Saif MW; Black G; Johnson M; Russo S; Diasio R
Cancer Chemother Pharmacol; 2006 Dec; 58(6):771-5. PubMed ID: 16552574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
